Find Academic Supervisors

Thomas Perlmann is a Professor in Molecular Developmental Biology at the Karolinska Institutet , leading research at the Department of Cell and Molecular Biology and serving as Director of the Stockholm Branch of the Ludwig Institute for Cancer Research. He also holds the position of Secretary General of the Nobel Assembly and Nobel Committee for Physiology or Medicine since 2016. Ph.D. , Karolinska Institutet, 1991 M.Sc. , Stockholm University, 1987 Research Interests : The Perlmann lab investigates the specification and maintenance of dopamine neurons in the central nervous system, with a focus on transcriptional regulation , signaling pathways , and regenerative medicine applications for Parkinson’s disease and other neurodegenerative disorders. His work bridges developmental biology and neuroscience , emphasizing the role of transcription factors in neuronal identity and function. Recent Research Trends : Perlmann’s recent publications highlight the use of single-cell RNA sequencing to dissect dopamine neuron heterogeneity , epigenetic regulation during development, and transcriptomic changes in Parkinson’s disease models. His studies increasingly leverage multiomics and bioinformatics to map neuronal lineage trajectories and gene expression dynamics. Scientific Awards : Royal Medal by HM the King (2025) Nicholson Lecturer, Rockefeller University (2011) Göran Gustafsson Prize in Molecular Biology (1999) Eric K. Fernström Young Investigator Prize (1997) Advising & Collaborations : While no student names are explicitly listed, Perlmann collaborates extensively with researchers such as Malin Parmar , Agnete Kirkeby , and Per Svenningsson on projects related to neuronal development and cell therapy . His lab receives funding from institutions like the Ludwig Institute for Cancer Research . Labs & Teams : The Perlmann Lab at Karolinska Institutet includes researchers like Linda Gillberg , Laura Lahti , and Behzad Yaghmaeian Salmani , who work on mouse models , single-cell transcriptomics , and bioinformatics to study dopamine neuron biology.

• Developmental Biology
• Neurosciences
• Dopamine Neurons
• +4 more

Overview Sebastian Schuck is a Professor of Biochemistry and Molecular Cell Biology at Heidelberg University's Biochemistry Center (BZH). His research focuses on organelle homeostasis, particularly the endoplasmic reticulum (ER), with emphasis on ER membrane biogenesis, ER-phagy, and SHRED pathways. He leads an international team investigating how cells adapt ER structure and function under stress or disease conditions. Education & Career Since 2021: Professor at Heidelberg University BZH 2013–2021: Independent Group Leader at Heidelberg University's Center for Molecular Biology 2006–2013: Postdoc with Peter Walter at UCSF 2001–2006: PhD and Postdoc with Kai Simons at Dresden's Max Planck Institute 1995–2000: Biochemistry studies at Universities of Hannover and Tübingen Research Interests Dr. Schuck's lab explores molecular mechanisms underlying ER homeostasis, including: 1. ER expansion during stress via lipid synthesis 2. Microautophagy-mediated ER degradation via ESCRT machinery 3. SHRED pathway regulation of proteasomal degradation of misfolded proteins 4. Links between ER stress and neurodegenerative diseases/cancer Awards & Honors No specific awards listed, but recognized for pioneering contributions to understanding microautophagy and ER quality control mechanisms. Advising & Collaborations Advised over 20 PhD/Master's students and postdocs Collaborations with Carlos Bas-Orth (MPI Biochemistry), Liam Holt (NY), and others Labs & Teams Current lab includes 10+ members focusing on: - Human ER morphogenesis - Microautophagy dynamics - SHRED pathway mechanisms

• Cell Biology
• Molecular Biology
• Membrane Biology
• +4 more

Jennifer L. Clarke is a Professor in the Department of Statistics at the University of Nebraska–Lincoln and Director of the Quantitative Life Science Initiative. She holds leadership roles in enabling big data integration across the University of Nebraska system through collaborative research programs. Her affiliations include the Institute of Agriculture and Natural Resources (IANR) and the College of Agriculture and Natural Resources. Dr. Clarke's research focuses on statistical methodology for high-dimensional data, computational biology, bioinformatics, and bacterial genomics. Her work bridges statistical innovation with applications in oncology, microbiome analysis, and agricultural phenomics. Key areas include predictive modeling, machine learning, and genomic/metagenomic data integration. Her recent publications span cancer biomarker discovery, plant phenotyping methodologies, and microbial community analysis, reflecting her interdisciplinary approach. Articles emphasize translational applications like therapeutic target identification and precision agriculture. Dr. Clarke leads initiatives fostering collaboration between statisticians and domain scientists, including the Quantitative Life Science Initiative and contributions to the Agricultural Genome-to-Phenome Initiative (AG2PI). Her work advances data-driven solutions for healthcare and food security challenges. Notable projects include developing statistical tools for microbiome studies, analyzing root architecture via 3D imaging, and investigating cranberry-derived compounds' cancer-inhibitory mechanisms. Her methodological contributions include hybrid clustering techniques and predictive model validation frameworks.

• Statistical Methodology
• Bioinformatics/Computational Biology
• Data Mining/Machine Learning
• +3 more

Michael J. Ragusa is an Associate Professor of Chemistry at the Department of Chemistry, College of Arts and Sciences, Dartmouth College , specializing in molecular mechanisms of selective autophagy . His research integrates structural biology , biochemical reconstitution , and cell biology to understand how cells degrade toxic components like damaged organelles. Education: B.S. in Chemistry from Siena College, Ph.D. in Biochemistry from Brown University His work focuses on autophagy , particularly the role of Atg proteins in membrane tethering and cargo selection. His lab has published extensively on mitophagy , ALFY , and Atg11 , linking defects in these pathways to cancer , neurodegeneration , and infectious diseases . Recent studies highlight mechanisms of vesicle clustering and dimerization-dependent membrane interactions . Dr. Ragusa teaches courses such as CHEM 5: General Chemistry , CHEM 42: Biological Chemistry II , and CHEM 95.05: Protein Crystallography . His lab employs techniques like X-ray crystallography , NMR spectroscopy , and membrane reconstitution to dissect protein-lipid interactions.

• Structural Biology
• Biochemical Reconstitution
• Autophagy
• +5 more

David W. Christianson is the Roy and Diana Vagelos Professor in Chemistry and Chemical Biology at the University of Pennsylvania's School of Arts & Sciences. His research focuses on structural and chemical biology of metalloenzymes, particularly histone deacetylases (HDACs) and terpene biosynthesis enzymes. He holds a B.A. from Harvard College (1983), A.M. and Ph.D. from Harvard University (1985, 1987). Education: A.B. in Chemistry, Harvard College (1983) A.M. in Chemistry, Harvard University (1985) Ph.D. in Chemistry, Harvard University (1987) Research interests include HDAC structure-function relationships, terpene cyclase catalysis, and enzyme architecture. Key findings include HDAC6's role in cancer therapy, HDAC10’s identification as a polyamine deacetylase, and cryo-EM studies of assembly-line terpene synthases. Articles Trends: Recent work emphasizes selective HDAC inhibitors (e.g., difluoromethyl-oxadiazoles for HDAC6), structural insights into terpene synthase dynamics, and engineering substrate channeling in bifunctional enzymes. Awards: Over 20 honors, including the Searle Scholar Award, Guggenheim Fellowship, and Lindback Teaching Award. He also serves as a Visiting Professor at Harvard and holds fellowships at institutions like the Royal Society of Chemistry. Advising & Grants: Advised numerous students (not listed explicitly). Active in NIH-funded projects on HDAC inhibitors and terpene biosynthesis. Lab fosters interdisciplinary approaches, combining crystallography, cryo-EM, and synthetic chemistry. Labs/Teams: Leads the Christianson Lab at Penn Chemistry, focusing on metalloenzyme mechanisms and drug discovery. Collaborates with groups at NIH, industry partners, and international institutions like the University of Cambridge.

• Biochemistry
• Structural Biology
• Enzymology
• +3 more

Olga Vitek is a Professor at Northeastern University's Khoury College of Computer Sciences, with affiliated faculty status in the Department of Chemistry and Chemical Biology. Her research bridges statistical science and machine learning with mass spectrometry-based proteomics and systems biology, focusing on developing open-source software tools like MSstats and Cardinal for quantitative proteomic analyses and imaging. Education: PhD in Statistics (Purdue University), Postdoc at the Ruedi Aebersold Lab (Institute for Systems Biology) Leadership: Director of the Barnett Institute for Chemical and Biological Analysis Her work emphasizes: Statistical experimental design Signal detection in complex mass spectrometry data Causal inference in biomolecular networks Reproducible computational infrastructure Recent publications highlight advancements in quantitative proteomics , mass spectrometry imaging , and causal modeling , with applications spanning cancer research, immunology, and clinical diagnostics. Notable trends include deep learning integration for image analysis and open-source tool development for scalable, transparent workflows. Scientific accolades: Elected Fellow of the American Statistical Association 2021 Gilbert S. Omenn Computational Proteomics Award NSF CAREER award Chan-Zuckerberg Essential Open-source Software award Senior Member, International Society for Computational Biology

• Statistical Science
• Machine Learning
• Mass Spectrometry
• +5 more

Thomas Melia is a Professor of Cell Biology at the Yale School of Medicine, part of Yale University. He leads the Melia Lab, focusing on autophagosome biogenesis and membrane dynamics during autophagy. His research integrates cell-based assays with advanced imaging techniques like electron cryo-microscopy. Key areas include understanding membrane sources for autophagosomes, lipid transport mechanisms, and organelle formation under cellular stress. Education: PhD in Biochemistry from Baylor College of Medicine (1999), BS in Biological Sciences from Carnegie Mellon University (1992) Research Interests: Autophagy, lysosomal biology, membrane trafficking, and protein aggregate clearance Lab Affiliations: Collaborates with departments like Biochemistry, Quantitative Biology, and Molecular Cell Biology Melia's work bridges molecular mechanisms with cellular function, particularly in how cells respond to starvation or pathogen invasion by degrading cytosolic components. Recent studies highlight roles for dynamin-like proteins in nuclear autophagy and lipid transfer proteins in organelle biogenesis.

• Autophagy
• Cell Biology
• Membrane Biology
• +3 more

Rui Kang, MD, PhD, is an Associate Professor in the Surgery Department at the University of Texas Southwestern Medical Center. Her research focuses on molecular mechanisms of pancreatic cancer, ferroptosis, and sepsis, with particular attention to tumor microenvironments and immunological pathways. She holds a medical degree and PhD from Chinese institutions (Xiangya School of Medicine and Norman Bethune College of Medicine) and completed postgraduate training at the University of Pittsburgh Cancer Institute. Dr. Kang’s work is supported by the NIH, and she contributes to editorial boards of oncology and gastroenterology journals. Her research interests span pancreatic cancer biology, ferroptosis regulation, and the interplay between cell death mechanisms and immune responses. Notable areas include investigating how platelet activation hinders antitumor immunity, mitochondrial-driven ferroptosis pathways, and the role of glutathione metabolism in cancer therapy resistance. Recent studies explore novel cell death modalities like triaptosis and alkaliptosis, alongside metabolic drivers of disease progression. Dr. Kang has authored dozens of peer-reviewed articles and book chapters, contributing to guidelines on ferroptosis detection and therapeutic strategies. Her work bridges basic science and clinical applications, emphasizing translational research in oncology and immunology.

• Pancreatic Cancer
• Ferroptosis
• Cancer Biology
• +4 more

Dr. Stephanie de Alcantara Fernandes is a Minerva Fast Track Group Leader at the Max Planck Institute for Biology of Ageing in Cologne, Germany, where she leads research on muscle metabolism and aging. Her laboratory investigates how spatial and functional regulation of mTORC1 signaling influences skeletal muscle health, growth, and regeneration throughout the lifespan, with implications for understanding and promoting healthy aging. Dr. Fernandes completed her academic training through a distinguished path: PhD in Biology (Summa cum laude, with distinction), University of Cologne/Max Planck Institute for Biology of Ageing (2017-2023) Master of Science in Genetics, University of São Paulo (2015-2017) Bachelor of Science in Biological Sciences, University of São Paulo (2009-2014) Exchange year at University of Birmingham, UK (2013) Her research focuses on skeletal muscle biology, particularly the balance between anabolic and catabolic processes that maintain muscle health. Dr. Fernandes investigates how mTORC1 (mechanistic Target of Rapamycin Complex 1), a central signaling hub, is spatially organized within cells to selectively regulate specific cellular functions in response to different nutrient sources. Her work reveals that mTORC1 is not simply "on or off" but can be finely tuned to control distinct processes in different cellular compartments, particularly in skeletal muscle cells. A key aspect of her research examines how these regulatory mechanisms change with age, contributing to age-related muscle loss (sarcopenia). By understanding the molecular basis of muscle maintenance and regeneration, her laboratory aims to identify targets for interventions that could promote healthier aging and prevent age-related decline in muscle function. Analysis of Dr. Fernandes' publication record shows a clear trajectory of increasingly independent research focused on mTORC1 signaling, nutrient sensing, and their roles in aging and muscle biology. Her most recent work demonstrates sophisticated understanding of mTORC1's spatial regulation, revealing how different pools of mTORC1 respond to distinct amino acid sources to control specific cellular processes. This research bridges fundamental cell biology with translational applications for aging-related conditions. Dr. Fernandes has received numerous prestigious awards recognizing her scientific excellence: Minerva Fast Track Fellowship (2025) - Group Leader Position for Outstanding Female Scientists from Max Planck Society Graduate School for Biological Sciences (GSfBS) doctoral award for 2023 (2025) World Muscle Society Fellowship (2016) Cologne Graduate School of Ageing Research fellowship (2017-2020) Master's scholarship from São Paulo Research Foundation (2015-2017) Science Without Borders Scholarship from Brazilian Council for Scientific and Technological Development (2013) As a newly appointed Group Leader through the Minerva Fast Track program, Dr. Fernandes is establishing her independent research program with substantial institutional support. Her laboratory combines advanced techniques including high-throughput omics approaches (proteomics, metabolomics), molecular biology, biochemistry, cell biology, and super-resolution microscopy. She utilizes multiple model systems including mouse models, skeletal muscle cell lines, and iPSC-derived skeletal muscle cells to identify evolutionarily conserved mechanisms relevant to human health. Dr. Fernandes leads the Minerva Fast Track Group at the Max Planck Institute for Biology of Ageing, which focuses specifically on "Muscle metabolism and aging." Her team investigates how selective mTORC1 signaling is coordinated between different skeletal muscle cell types and how it changes with age, with the ultimate goal of understanding how muscle health can be maintained throughout life.

• Muscle Metabolism
• Aging Research
• mTORC1 Signaling
• +6 more

Charles L. White is Professor of Pathology at UT Southwestern Medical Center, where he holds the Nancy R. McCune Distinguished Chair in Alzheimer Disease Research. He has served as Director of Neuropathology at UT Southwestern since completing his residency and fellowship training in anatomic pathology and neuropathology at Johns Hopkins in 1983. Dr. White also directs the Neuropathology Core of the UT Southwestern Alzheimer Disease Research Center (established 1988) and the Winspear Family Special Center for Research on the Neuropathology of Alzheimer's Disease (established 2002). Dr. White completed his medical and pathology training at Johns Hopkins University, establishing a career focused on neurodegenerative brain disorders. His educational background forms the foundation for his dual expertise in clinical neuropathology and research investigation. Dr. White's research spans multiple critical areas of neuropathology: Pathological mechanisms of Alzheimer's disease and related dementias Tau protein aggregation and propagation across neurodegenerative conditions Diagnostic criteria and staging systems for various neuropathologies Genetic and molecular underpinnings of frontotemporal lobar degeneration Chronic traumatic encephalopathy and its relationship to other neurodegenerative conditions Development of artificial intelligence approaches for neuropathological assessment Analysis of Dr. White's extensive publication record reveals a consistent focus on defining and characterizing neurodegenerative disease processes through rigorous pathological examination. His work frequently addresses diagnostic criteria, disease classification systems, and the molecular mechanisms underlying various neurodegenerative conditions. There is particular emphasis on tau pathology across multiple disease states, including Alzheimer's disease, primary age-related tauopathy (PART), and chronic traumatic encephalopathy (CTE). His research often involves large collaborative efforts with multiple institutions, reflecting the complex, multidisciplinary nature of modern neuropathological research. Dr. White has received significant recognition for his contributions to the field: Award for Meritorious Contributions to Neuropathology from the American Association of Neuropathologists (2020) Nancy R. McCune Distinguished Chair in Alzheimer Disease Research As an educator and mentor, Dr. White serves as Training Director for the Neuropathology Fellowship program at UT Southwestern, an ACGME-accredited, 2-year training program. Twenty-two trainees have completed the program and become board certified by the American Board of Pathology in the subspecialty of Neuropathology. He has held significant leadership positions including past president of the American Association of Neuropathologists, the national professional organization for neuropathologists in the US. His mentorship extends to numerous research collaborations where he guides junior investigators in neuropathological research methods and interpretation. Dr. White directs multiple research centers including the Neuropathology Core of the UT Southwestern Alzheimer Disease Research Center and the Winspear Family Special Center for Research on the Neuropathology of Alzheimer's Disease. His laboratory work focuses on understanding the pathological mechanisms of neurodegenerative diseases, particularly those involving protein misfolding and aggregation. His team employs advanced techniques including immunohistochemistry, molecular pathology, and increasingly, artificial intelligence approaches to analyze neuropathological specimens.

• Neuropathology
• Neurodegenerative diseases
• Alzheimer's Disease
• +3 more

Matthias Peter is a Professor of Biochemistry at ETH Zurich, leading research into mechanisms governing cell growth and division. His laboratory focuses on ubiquitin-dependent regulation of DNA replication and mitosis, and autophagy's role in cellular quality control. He chairs the Department of Biology (2011-2015) and holds leadership roles in Switzerland's research infrastructure, including Vice Chair of ScopeM's microscopy platform. His academic career includes roles at ISREC (1996-2002) and postdoctoral training at UCSF (1991-1996). Education: PhD in Biochemistry from ISREC (1991), ETH Zurich diploma in Gene Technology (1987). Research interests span molecular mechanisms of cell division, ubiquitin systems, and autophagy. Awards include ERC Advanced Grant (2011) and UBS Excellence in Research (2002). Leadership: Member of Swiss National Research Council, SNF selection committee, and SWTR council. Over 20 years of committee service in national research programs. His lab's work is published in top journals like Science, Nature, and Molecular Cell.

• Biochemistry
• Cell Biology
• Cell division
• +7 more

Dr Andrew Grierson is a Senior Lecturer in Neuroscience at the School of Medicine and Population Health, University of Sheffield, based at the Sheffield Institute for Translational Neuroscience (SITraN). His research focuses on molecular mechanisms of neurodegenerative diseases with translational applications. His educational background includes: PhD in Molecular Genetics from the University of Sheffield (1991-1994) BSc in Genetics from the University of Sheffield (1988-1991) Dr Grierson's work centers on axonal transport regulation in motor neurone disease (MND) and hereditary spastic paraplegia (HSP) , utilizing zebrafish and mouse models to investigate disease mechanisms and therapeutic interventions. Current projects include HDAC6 inhibition studies for CMT2A and HSP, C9ORF72 protein function analysis in ALS, and spastin gene replacement therapy development. His laboratory emphasizes preclinical translation with strong industry and charity partnerships. Analysis of his 15 most recent publications (2013-2022) reveals consistent focus on ALS/MND pathophysiology, with increasing emphasis on C9ORF72-related mechanisms , mitochondrial dysfunction , and therapeutic target validation . The work bridges basic molecular neuroscience and clinical applications, predominantly using in vivo models and translational biomarkers . Dr Grierson supervises multiple PhD students and collaborates with Pamela Shaw and Bob Johnston at Sheffield. His research group includes technicians Katie Adamson and Gary Shaw, operating within SITraN's specialized facilities for neurodegenerative disease research.

• Neurodegenerative Diseases
• Axonal Transport
• Motor Neurone Disease
• +3 more

Helle F Jørgensen is an Associate Professor at the University of Cambridge, based at the Victor Phillip Dahdaleh Heart and Lung Research Institute (VPD-HLRI). She is a Principal Investigator in the Cardiovascular and Respiratory Medicine (CaRM) section of the Department of Medicine and a key member of the Cambridge Cardiovascular Interdisciplinary Research Centre and the British Heart Foundation (BHF) Cambridge Centre of Excellence. Dr. Jørgensen earned her PhD in molecular biology from Aarhus University in 2000 under Professor Brian Clarke. Her postdoctoral training included research on DNA-methylation-binding factors with Professor Sir Adrian Bird at the University of Edinburgh and investigations into transcription factors and epigenetic mechanisms in embryonic stem cell maintenance with Professor Dame Amanda G Fisher at the London Institute of Medical Research. Her research focuses on vascular smooth muscle cell (VSMC) plasticity and heterogeneity in vascular health and disease. She has demonstrated that a small number of pre-existing VSMCs undergo extensive proliferative expansion to generate the majority of cells in atherosclerotic lesions, with similar clonal expansion observed in other vascular disease models. Using single-cell transcriptome profiling, her group has revealed substantial VSMC heterogeneity both in lesions and healthy arteries. This work has significant implications for understanding VSMC behavior and developing selective targeting strategies for disease-associated VSMCs. Her laboratory employs single-cell approaches, lineage tracing, and global epigenetic profiling to study how gene expression programs are regulated and impact phenotypic plasticity in genetic disease models and human tissue. They investigate how VSMCs contribute to atherosclerosis development, the disease underlying heart attack and stroke, with focus on how these cells downregulate their contractile phenotype in response to injury and inflammation. British Heart Foundation Senior Basic Science Research Fellow Dr. Jørgensen's work has important translational implications for cardiovascular medicine. Her research on VSMC heterogeneity and clonal expansion provides critical insights into atherosclerosis pathogenesis and identifies potential therapeutic targets. As part of the BHF Cambridge Centre of Excellence, her research contributes to the broader mission of improving cardiovascular and lung health worldwide through collaborative research across university, NHS, commercial, and charitable sectors. The Jorgensen Group operates within the Victor Phillip Dahdaleh Heart and Lung Research Institute, a state-of-the-art facility that brings together researchers and clinicians to advance understanding of cardiovascular and respiratory diseases. Her work bridges fundamental molecular mechanisms with clinical applications in vascular medicine.

• Vascular Biology
• Cardiovascular Disease
• Atherosclerosis
• +5 more

Dr. Jason Mills is the Herman Brown Endowed Professor at Baylor College of Medicine, where he serves as Chief of Research and Vice Chief in the Department of Gastroenterology & Hepatology. He is also Co-Director of the Texas Medical Center Digestive Disease Center and Co-Associate Director for Cancer Research Training and Education at the Dan L Duncan Comprehensive Cancer Center. Dr. Mills leads the Mills Lab, which focuses on cellular reprogramming and cancer mechanisms. Dr. Mills received his AB from Washington University in St. Louis (1989), followed by an MD-PhD from the University of Pennsylvania School of Medicine (1997). He completed his postdoctoral fellowship at Washington University Medical Center (2002). Dr. Mills' research centers on paligenosis, a cellular program he identified that allows mature cells to return to a regenerative state. His work explores how this process contributes to tissue repair but also increases cancer risk through the development of precancerous conditions like metaplasia. Using organoid models derived from patient cancer cells and genetic mouse strains, his lab investigates the molecular mechanisms of cellular plasticity in gastric biology, with implications for cancer prevention and treatment. His research integrates cell biology, metabolism, and translational approaches to understand how cells adapt to stressors. Analysis of Dr. Mills' recent publications reveals a strong focus on the molecular mechanisms of paligenosis and its role in gastric metaplasia and cancer development. His work spans basic cell biology investigations of cellular reprogramming to translational studies using patient-derived organoids. Key themes include the role of transcription factors like SOX9, metabolic regulation of cell fate decisions, and the identification of biomarkers for cancer progression. Dr. Mills has received several prestigious awards, including: Excellence in Research and Leadership Award from Baylor College of Medicine (2022) Top Reviewer for Gastroenterology from the American Gastroenterological Association (2022) Membership Induction to the Association of American Physicians (2022) Research Mentor Award from the AGA Institute Council (2022) Dr. Mills currently mentors several graduate students and postdoctoral researchers in the Mills Lab. His research is supported by multiple NIH grants totaling over $30 million, including R01 grants from NCI and NIDDK focused on mechanisms of paligenosis, metaplasia, and gastric cancer development. These grants support investigations into cellular reprogramming, stem cell differentiation, and therapeutic approaches for precancerous lesions. The Mills Lab maintains a collection of organoids derived from patient cancer cells and utilizes advanced techniques including single-cell RNA sequencing and spatial transcriptomics. The lab collaborates with clinicians at Baylor College of Medicine and across the Texas Medical Center to translate basic findings into clinical applications for personalized cancer treatment.

• Paligenosis
• Cellular Reprogramming
• Stem Cells
• +6 more

Frank Longo is a Professor in the Department of Neurology and Neurological Sciences at Stanford University School of Medicine. He actively teaches across the neuroscience curriculum including Medical Scholars Research (NENS 370), Directed Reading courses (NEPR 299/NENS 299), Graduate Research (NENS 399/NEPR 399), and Early Clinical Experience (NENS 280), demonstrating his commitment to training the next generation of neuroscientists and clinicians. His research program centers on neurodegenerative diseases with particular emphasis on Alzheimer's, Huntington's, and Parkinson's diseases. Longo investigates the therapeutic potential of neurotrophin receptor modulation (especially p75NTR and TrkB) using small-molecule ligands like LM11A-31, exploring mechanisms spanning protein aggregation, synaptic dysfunction, neuroinflammation, and metabolic dysregulation. His work bridges molecular neuroscience with translational applications, utilizing advanced techniques including transcriptomics, neuroimaging, and biomarker analysis in cellular and animal models. Analysis of his 2024-2025 publications reveals consistent focus on targeting neurotrophin pathways to reverse disease phenotypes. Key themes include: 1) Development of small-molecule modulators for p75NTR/TrkB to rescue synaptic and cognitive deficits; 2) Biomarker discovery for early detection (e.g., plasma Aβ42/Aβ40 ratios); 3) Mechanistic studies on autophagy, white matter changes, and metabolic dysfunction; and 4) Leadership in collaborative initiatives like the TREAT-AD Center for target validation. His research demonstrates both breadth across neurodegenerative disorders and depth in neurotrophin signaling mechanisms. Through undergraduate and graduate research courses, Longo mentors students in neuroscience research despite no specific advisees being listed. His extensive publication record and involvement in multi-institutional consortia (including EU-US task forces) indicate significant research funding and national leadership in neurodegenerative disease research, though specific grant details aren't provided in the source material.

• Alzheimer's Disease
• Huntington's Disease
• Parkinson's Disease
• +5 more